On 03 September 2025, Hoffmann-La Roche conducted a study is to assess the long-term safety and to explore the efficacy of ...

“Without appropriate preparation and intervention, patients may experience significant hypoxemia in flight, which can lead to ...

AstraZeneca said on Wednesday its asthma drug Fasenra failed to control the rate of flare-ups in patients with chronic ...

AstraZeneca ( NASDAQ: AZN) said that the late-stage trial for its medication Fasenra (benralizumab) in patients suffering ...

Saphnelo, which generated $304 million in sales in the first half of this year, is projected to achieve peak annual sales of ...

A recent study reveals that COPD, or Smokers' Disease, is impacting younger individuals. Doctors in Delhi are observing a ...

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...

A major global study published in The Lancet has found that while deaths from chronic diseases such as cancer, heart disease, ...

Content by Health System. With Asthma Peak Week typically during the middle of September, now is a great time to learn the ...

Biologics targeting type 2 inflammation show strong efficacy in eosinophilic COPD, while non-type 2 approaches remain ...

AstraZeneca (AZN) announced on Wednesday that its late-stage trial of Fasenra in patients with chronic obstructive pulmonary ...

The rise in mortality was mainly due to ischaemic heart disease and diabetes, including diabetic kidney disease, affecting ...